Thyroid Function Test Evaluation in Prostate Cancer Patients in Khartoum State

Abdalla Ali

doi:10.37319/

Abdalla Ali

a:1:{s:2:"en";s:20:"Associate Professor ";}

Keywords

Prostate cancer (PCa), thyroid hormones (TH) namely T3, T4, TSH, prostate-specific antigen (PSA

Abstract

Abstract Introduction: Thyroid hormones (TH) are key regulators of essential cellular processes, including proliferation, differentiation, apoptosis, and metabolism. Thyroid hormones have an important role in the development of prostate cancer. So this study aims to assess thyroid function tests among prostatic cancer patients. methods: Total group study100, fifty Prostatic cancer patients as a case study and 50 healthy men as the control group, blood samples were collected for measurement for thyroid function test and Prostate Antigen by Tosoh TM device (China) and enzyme-linked immune sorbent assay (ELISA) Fortress TM. Results: Statistical analysis of test results of the case study: the mean and SD± PSA= (31.8 ± 12.5 ) , T3 = (3.3 ± 1.3) , T4 = (119.58 ± 46.21 ) and TSH =(4.6 ± 3.4) . For each P-value 0.0001 when compared to the control group, the frequency of thyroid disorders among case study participants is hyperthyroidism (33 = 66%), normal (14 = 28%), and hypothyroidism (3 = 6%). Conclusion: Hyperthyroidism is the most common thyroid disorder among patients with prostatic cancer.

Abstract 15 | Full text PDF Downloads 12

References

1. Jemal A, Bray F, Forman D, O'Brien M, Ferlay J, Center M, et al. Cancer burden in Africa and opportunities for prevention. Cancer. 2012;118(18):4372–84.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
3. Ferlay JEM, Lam F, Colombet M, Mery L, Pineros M, Znaor A, Soerjomataram I, et al. Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer. Accessed 02 February 2019.
4. Rasool M, et al. Association of thyroid dysfunction with breast and prostate cancer. Journal of the College of Physicians and Surgeons Pakistan. 2018;28(4):284-287.
5. Pinto M, Soares P, Ribatti D. Thyroid hormone as a regulator of tumor-induced angiogenesis. Cancer Lett. 2011;301:119–126.
6. Hsieh ML, Juang HH. Cell growth effects of triiodothyronine and expression of thyroid hormone receptor in prostate carcinoma cells. J Androl. 2005;26:422–428.
7. Tsui KH, Hsieh WC, Lin MH, Chang PL, Juang HH. Triiodothyronine modulates cell proliferation of human prostatic carcinoma cells by downregulation of the B-cell translocation gene 2. Prostate. 2008;68:610–619.
8. Yen PM. Physiological and molecular basis of thyroid hormone action. Physiol Rev. 2001;81:1097–1142.
9. Baskin HJ, Cobin RH, Duick DS, Gharib H, Guttler RB, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract. 2002;8:457–469.
10. Partin AW, Oesterling JE. The clinical usefulness of prostate-specific antigen: update 1994. J Urol. 1994;152:1358-1368.
11. Yeh S, et al. Low serum free triiodothyronine levels predict increased risk of recurrence in patients with localized prostate cancer undergoing radical prostatectomy. Clinica Chimica Acta. 2019;496:1-5.
12. Ferraldeschi R, et al. Triiodothyronine (T3) levels in locally advanced prostate cancer patients undergoing neoadjuvant treatment and their association with clinical outcomes. European Urology Supplements. 2019;18(1):e2420-e2421.
13. Goemann IM, Romitti M, Meyer ELS, Wajner SM, Maia AL. Role of thyroid hormones in the neoplastic process: an overview. Endocr Relat Cancer. 2017;24:R367-R385.
14. Bilek R, Gkonos PJ, Tavianini MA, Smyth DG, Roos BA. The thyrotrophin-releasing hormone (TRH)-like peptides in rat prostate are not formed by expression of the TRH gene but are suppressed by thyroid hormone. J Endocrinol. 1992;132:177-184.
15. Silva JF, et al. Thyroid hormone action on the rat ventral prostate. Brazilian Journal of Medical and Biological Research. 1990;23(2):169-172.
16. Lehrer S, Diamond EJ, Bajwa AM, Kornreich R, Stagger S, Stone NN, Droller MJ, Stock RG. Association between serum triiodothyronine (t3) level and risk of disease recurrence in men with localized prostate cancer. Prostate Cancer Prostatic Dis. 2001;4:232-234.
17. Dogra P, Paudel R, Panthi S, Cassity E, Tannock LR. Low yield of thyroid-function tests in adult hospitalized patients — a retrospective analysis. Dove Press; 6 July 2020. pp. 343—349.
18. Jun HL, Yeon WP, Sung WL. The relationship between thyroid hormone levels and lower urinary tract symptoms/benign prostatic hyperplasia. World J Men's Health. 2019;37(3):364-371.
19. Krashin E, Piekiełko-Witkowska A, Ellis M, Ashur-Fabian O. Thyroid hormones and cancer: a comprehensive review of preclinical and clinical studies. Front Endocrinol (Lausanne). 2019;10:59.
20. Şenel C, Tuncel A, Aslan Y, Berker D, Çatak M, Güler S, Balcı M. Impact of thyroid hormones on serum prostate specific antigen level in patients with benign thyroid disorders. Journal of Urological Surgery. 2020;7(4):290-294.
21. Yeh S-T, et al. Low serum free triiodothyronine levels predict increased risk of recurrence in patients with localized prostate cancer undergoing radical prostatectomy. Clinica Chimica Acta. 2019;496:1-5.
22. Silva JF, et al. Thyroid hormone action on the rat ventral prostate. Brazilian Journal of Medical and Biological Research. 1990;23(2):169-172.
23. Ferraldeschi R, et al. Triiodothyronine (T3) levels in locally advanced prostate cancer patients undergoing neoadjuvant treatment and their association with clinical outcomes. European Urology Supplements. 2019;18(1):e2420-e2421.
24. Şenel C, Tuncel A, Aslan Y, et al. Impact of thyroid hormones on serum prostate specific antigen level in patients with benign thyroid disorder. J Urol Surg. 2020;7(4):290-294.
25. OVČARIČEK PP, FRÖBE A, VERBURG FA, et al. Association of triiodothyronine levels with prostate cancer histopathological differentiation and tumor stage. Anticancer Research. 2020;40(4):2323-2329. https://doi.org/10.21873/anticanres.14199
26. Garber JR, Cobin RH, Gharib H, et al. "Clinical Practice Guidelines for Hypothyroidism in Adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association." Thyroid. 2012;22(12):1200-1235. Link,
27. Mondul AM, Weinstein SJ, Bosworth T, Remaley AT, Virtamo J, et al. Circulating thyroxine, thyroid stimulating hormone, and hypothyroid status and the risk of prostate cancer. PLoSONE7. 2012;10:e47730. doi: 10.1371/journal.pone.0047730
28. Hsieh ML, Juang HH. Cell growth effects of triiodothyronine and expression of thyroid hormone receptor in prostate carcinoma cells. J Androl. 2005;26:422–428.
29. Tsui KH, Hsieh WC, Lin MH, Chang PL, Juang HH. Triiodothyronine modulates cell proliferation of human prostatic carcinoma cells by downregulation of the B-cell translocation gene 2. Prostate. 2008;68:610–619.
30. Lehrer S, Diamond EJ, Stone NN, Stock RG. Serum thyroid-stimulating hormone is elevated in men with Gleason 8 prostate cancer. BJU Int. 2005;96:328–329.
31. Lehrer S, Diamond EJ, Stone NN, Droller MJ, Stock RG. Serum triiodothyronine is increased in men with prostate cancer and benign prostatic hyperplasia. J Urol. 2002;168:2431–2433.
32. Hoption Cann SA, Qiu Z, van Netten C. A prospective study of iodine status, thyroid function, and prostate cancer risk: follow-up of the First National Health and Nutrition Examination Survey. Nutr Cancer. 2007;58:28–34.
33. Hellevik AI, Asvold BO, Bjoro T, Romundstad PR, Nilsen TI, et al. Thyroid function and cancer risk: a prospective population study. Cancer Epidemiol Biomarkers Prev. 2009;18:570–574.
34. Kumar CC. Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets. 2003;4: 123–131.

Full text PDF

Published

Jan 15, 2025

DOI: https://doi.org/10.37319/

How to Cite

1.

Thyroid Function Test Evaluation in Prostate Cancer Patients in Khartoum State. Iraqi Natl J Med [Internet]. 2025 Jan. 15 [cited 2025 Jan. 22];7(1):3-8. Available from: https://iqnjm.com/index.php/homepage/article/view/170